Technology | Digital Pathology | May 29, 2019

Leica Biosystems Receives FDA Clearance for Aperio AT2 DX Digital Pathology System

Digital pathology system cleared for primary diagnosis following multi-center study at five clinical sites in the U.S.

Leica Biosystems Receives FDA Clearance for Aperio AT2 DX Digital Pathology System

May 29, 2019 — Leica Biosystems has received clearance from the U.S. Food and Drug Administration (FDA) to market its Aperio AT2 DX System for clinical diagnosis in the U.S.

A multi-center study supporting this clearance was conducted with pathologists at five clinical study sites in the U.S.:

  • University of California Davis;
  • Pacific Rim Pathology;
  • Dignity Health;
  • TriCore Reference Laboratories; and
  • Intermountain Healthcare.

One of the largest clinical concordance studies ever completed on digital whole slide images, the participating pathologists read approximately 16,000 cases. The study compared reads of pathology slides under a microscope with on-screen digital reads.  

The Aperio AT2 DX System is a high-throughput automated scanning and viewing platform. The platform will be launched commercially with clinical image management software for an integrated digital pathology workflow solution.

For more information: www.leicabiosystems.com

Related Content

Long-term Hormone Therapy Increases Mortality Risk for Low-PSA Men After Prostate Surgery
News | Prostate Cancer | September 16, 2019
Secondary analysis of a recent clinical trial that changed the standard of care for men with recurring prostate cancer...
Xifin Launches Version 6 of Laboratory Information System
News | Digital Pathology | September 05, 2019
Xifin announced the launch of the next evolution of its laboratory information system (LIS), Xifin LIS 6. The expanded...
News | Contrast Media | September 03, 2019
Researchers in South Korea have found that patients with family and personal history of allergic reactions to contrast...
An example of a treatment plan for radio-ablation of the heart to noninvasively treat cardiac arrhythmias. This concept is one of the key presentations at the 2019 ASTRO meeting. Image courtesy of Cyberheart. #ASTRO19 #ASTRO2019 #ASTRO

An example of a treatment plan for radio-ablation of the heart to noninvasively treat cardiac arrhythmias. This concept is one of the key presentations at the 2019 ASTRO meeting. Image courtesy of Cyberheart.

Feature | ASTRO | August 29, 2019
FDA Encourages Inclusion of Male Patients in Breast Cancer Clinical Trials
News | Women's Health | August 26, 2019
The U.S. Food and Drug Administration (FDA) released a new draft guidance that encourages including male patients in...
Moffitt Researchers Develop Model to Personalize Breast Cancer Radiation Treatment
News | Radiation Therapy | August 26, 2019
A personalized approach to cancer treatment has become more common over the last several decades, with numerous...
Philips Signs Agreement to Create Taiwan's First Fully Digitalized Pathology Department
News | Digital Pathology | August 23, 2019
Philips announced that Taipei Veterans General Hospital (TPVGH) will utilize the Philips IntelliSite Pathology Solution...
Vaping Impairs Vascular Function

Image courtesy of the American Heart Association

News | Magnetic Resonance Imaging (MRI) | August 21, 2019
Inhaling a vaporized liquid solution through an e-cigarette, otherwise known as vaping, immediately impacts vascular...
Some Pregnant Women Are Exposed to Gadolinium in Early Pregnancy
News | Women's Health | August 20, 2019
A small but concerning number of women are exposed to a commonly used magnetic resonance imaging (MRI) contrast agent...